BUFFALO GROVE, Ill.--(BUSINESS WIRE)--RestorGenex Corporation (OTCQB: RESX), a specialty biopharmaceutical company initially focused on developing products for dermatology, ophthalmology and women’s health, today announced that Chief Scientific Officer David Sherris, Ph.D., will present scientific data on the Company’s proprietary RES-529 program in ophthalmology. Dr. Sherris’s presentation at the Cambridge Healthtech Institute conference is scheduled for Monday, October 6, 2014 at 4:55 pm (EDT) at the Westin Boston Waterfront Hotel.
RES-529 is a first-in-class inhibitor of the PI3K/Akt/mTOR pathway. Ocular disorders of retinal origin, as in wet age-related macular degeneration (AMD), have aberrant back of the eye vascularization. This aberrant vascularization is induced through a process known as angiogenesis. Numerous pro-angiogenic factors have been shown to reside in the eyes of patients with wet AMD. Many of such pro-angiogenic factors activate the PI3K/Akt/mTOR pathway ultimately resulting in aberrant back of the eye vascularization. One such factor is vascular endothelial growth factor (VEGF). Anti-VEGF technologies (Lucentis®, Eylea®) have been used successfully to treat wet AMD. However, a significant number of patients show minimal activity or are refractory to anti-VEGF treatment. As there are numerous pro-angiogenic factors in the eye of AMD patients in addition to VEGF, an agent having broader activity to inhibit multiple pro-angiogenic factors may be useful for treatment of such patients. RES-529 has been shown to inhibit a wide variety of pro-angiogenic factors. For this reason, RES-529 treatment was evaluated in two Phase I human clinical studies in wet AMD alone and in the presence of Lucentis®. Final results will be presented here indicating a lack of toxicity and preliminary evidence of activity.
Help employers find you! Check out all the jobs and post your resume.
